See more : MGX Minerals Inc. (XMG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Envoy Medical, Inc. (COCH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Envoy Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Investor AB (publ) (INVE-A.ST) Income Statement Analysis – Financial Results
- Asia Time Corporation (ATYM) Income Statement Analysis – Financial Results
- Diamond Bancshares, Inc. (DMNB) Income Statement Analysis – Financial Results
- Benchmark Holdings plc (BHCCF) Income Statement Analysis – Financial Results
- San Shing Fastech Corp. (5007.TW) Income Statement Analysis – Financial Results
Envoy Medical, Inc. (COCH)
About Envoy Medical, Inc.
Envoy Medical, Inc., a hearing health company, provides medical technologies for the hearing loss spectrum. Its products include hearing aids; Esteem middle ear implants; bone conduction devices; and Acclaim cochlear implants. Envoy Medical Corporation was formerly known as St. Croix Medical, Inc. and changed its name to Envoy Medical Corporation in December 2004. The company was founded in 1995 and is based in White Bear Lake, Minnesota.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 316.00K | 237.00K | 310.00K | 0.00 |
| Cost of Revenue | 789.00K | 957.00K | 769.00K | 0.00 |
| Gross Profit | -473.00K | -720.00K | -459.00K | 0.00 |
| Gross Profit Ratio | -149.68% | -303.80% | -148.06% | 0.00% |
| Research & Development | 8.96M | 4.52M | 3.94M | 0.00 |
| General & Administrative | 7.28M | 3.47M | 2.47M | 0.00 |
| Selling & Marketing | 1.67M | 885.00K | 0.00 | 0.00 |
| SG&A | 8.94M | 3.47M | 2.47M | 701.00 |
| Other Expenses | 0.00 | -7.22M | -1.80M | 0.00 |
| Operating Expenses | 17.90M | 7.99M | 6.41M | 701.00 |
| Cost & Expenses | 18.69M | 8.94M | 7.18M | 701.00 |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 133.00K | 75.00K | 71.00K | 206.30K |
| EBITDA | -18.24M | -8.63M | -6.80M | -700.00 |
| EBITDA Ratio | -5,771.52% | -3,641.77% | -2,193.55% | 0.00% |
| Operating Income | -18.37M | -8.71M | -6.87M | -700.00 |
| Operating Income Ratio | -5,813.61% | -3,673.42% | -2,216.45% | 0.00% |
| Total Other Income/Expenses | -11.54M | -7.22M | -1.80M | -1.00 |
| Income Before Tax | -29.91M | -15.92M | -8.68M | -701.00 |
| Income Before Tax Ratio | -9,464.56% | -6,718.57% | -2,798.39% | 0.00% |
| Income Tax Expense | 0.00 | -153.49K | -165.56K | -206.30K |
| Net Income | -29.91M | -15.92M | -8.68M | -701.00 |
| Net Income Ratio | -9,464.56% | -6,718.57% | -2,798.39% | 0.00% |
| EPS | -2.38 | -1.57 | -0.85 | 0.00 |
| EPS Diluted | -2.38 | -1.57 | -0.85 | 0.00 |
| Weighted Avg Shares Out | 12.55M | 10.15M | 10.15M | 60.38M |
| Weighted Avg Shares Out (Dil) | 12.55M | 10.15M | 10.15M | 60.38M |
Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events
FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company FDA approval to...
Envoy Medical's Fully Implanted Acclaim® Cochlear Implant Highlighted in Peer-Reviewed Publication
Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant
Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System
WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No....
Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients
Envoy Medical to Present at the LD Micro Main Event XVII
WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate...
Major Envoy Medical Investor Glen Taylor Discusses How Apple's AirPods Pro 2 Hearing Aid Announcement is a Potentially Positive Development for the Company
During “The Claman Countdown,” the billionaire investor and entrepreneur noted how hearing aid modes in next-gen wireless earbuds can work with Envoy Medical's fully implanted hearing devices
Envoy Medical Awarded Patent for Recharge System used with Implantable Battery
Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss
Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year
Bipartisan Senate Bill Seeks to Clarify that Implanted Active Middle Ear Hearing Devices are Prosthetics, Not Hearing Aids, Making Them Eligible for Medicare Coverage
Envoy Medical's FDA-Approved Esteem® Fully Implanted Active Middle Ear Hearing Device May Now Have an Opportunity to be a Coverable Benefit
Envoy Medical Announces Inclusion in the Russell Microcap Index
WHITE BEAR LAKE, MN, July 01, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (Nasdaq: COCH), a revolutionary hearing health company focused on fully implanted hearing systems, announces that FTSE Russell has selected the Company's shares for inclusion in...
Source: https://incomestatements.info
Category: Stock Reports